Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint

ABBOTT LABORATORIES

2024-Q3 EPS reported $2.38 revenue$30,976,000,000

Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
GAAP diluted EPS $0.94; adjusted diluted EPS $1.21; FY 2024 adj. EPS guidance raised to $4.64-$4.70.
FreeStyle Libre CGM sales >$1.6B (+20.7% organic); new $7B share repurchase authorized; quarterly dividend $0.55.
Partnered with Medtronic to connect CGM with insulin devices; launched OTC Lingo CGM in U.S.; completed VOLT-AF trial enrollment.
Nutrition organic +3.4% (Adult +9.1%); Diagnostics organic ex-COVID +3.3% (Core Lab +4.5%); Established Pharma organic +7.0%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.